Quipt Home Medical (QIPT) Proxy Filing summary

Executive summary

• A special meeting will be held for shareholders to vote on a proposed acquisition, where all outstanding shares will be acquired for $3.65 per share in cash, representing a 39.9% premium to the last trading price before announcement and a 46% premium to the 90-day VWAP on Nasdaq.

• The board unanimously recommends voting in favor, citing a robust strategic review, competitive process, and fairness opinions from Truist Securities and Evans & Evans confirming the offer is fair from a financial perspective.

• The transaction is structured as a plan of arrangement under British Columbia law, requiring both shareholder and court approval, and is expected to close in the first half of 2026, subject to regulatory and other customary conditions.

Voting matters and shareholder proposals

• Shareholders will vote on the arrangement resolution to approve the acquisition and may act on other business at the meeting.

• Approval requires at least 66 2/3% of votes cast and a simple majority excluding certain related parties, as per MI 61-101.

• Dissent rights are available to registered shareholders, allowing them to seek fair value for their shares if they object to the arrangement.

• If the arrangement is not approved, the company will remain public and shares will continue trading.

Board of directors and corporate governance

• The board and its strategic transactions committee conducted a comprehensive review, including engaging financial advisors and running a competitive process with multiple parties.

• Directors and executive officers holding 11.4% of shares have entered into voting agreements to support the deal.

• The board considered industry challenges, competitive pressures, and the certainty of all-cash consideration in its recommendation.